Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 919 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Immunomedics Veltuzumab showed efficacy in ITP

Veltuzumab, a humanized anti-CD20 antibody was constructed using the same human donor frameworks as epratuzumab. The results demonstrated that two doses of veltuzumab produced an overall objective response

Celladon Mydicar drug receives FDA fast track status

Mydicar is a genetically targeted enzyme replacement therapy designed to restore levels of SERCA2a, that regulates calcium cycling and contractility. The randomized double-blind placebo-controlled Phase 2 Calcium Up-regulation

Abbott, Reata partner to develop oral AIMs

AIMs activate the transcription factor Nrf2, that suppresses NF-?B, a transcription factor that is associated with chronic diseases such as multiple sclerosis, rheumatoid arthritis, chronic kidney disease, neurodegenerative

CeNeRx completes $4.85m financing

The company will use the proceeds of the financing for the completion of its ongoing Phase II trial of the improved formulation of antidepressant TriRima, besides using it